NT Pharma Announces 2015 Annual Results

" />

English

简体中文

繁體中文

한국어

日本語

Wednesday, 23 March 2016, 21:09 HKT/SGT

Records 41 Times Increase in Net Profit For The Year and Distributes Dividend for the First Time

HONG KONG, Mar 23, 2016 - (ACN Newswire) - China NT Pharma Group Company Limited ("NT Pharma" or the "Company") (stock code: 01011.HK) is pleased to announce the annual results of the Company and its subsidiaries (collectively, the "Group") for the year ended 31 December 2015 (the "Period").

From left to right: China NT Pharma Group Company Limited. Vice General Manager of Marketing and Sales Center Mr. ZHANG Jianfeng, CFO & Company Secretary Mr. CHIU Yu Kang, Chairman & CEO of the Group Mr. NG Tit and Assistant President & General Manager of R&D and Medical Center, Mr. GE Baoming

During 2015, the Group substantially dedicated its focus on expanding its proprietary product portfolio and developing its own research and development capabilities. The overall revenue of the Group for the year ended 31 December 2015 decreased slightly by 2.0% to RMB847.7 million, as compared with RMB864.6 million for the previous year. The Gross Margin increased by 8 percentage points to 53.3%. Operating profit for the year ended 31 December 2015 improved significantly, amounting to RMB135.9 million, as compared with an operating profit of RMB96.1 million for the previous year. The improvement in operating result was mainly due to (i) increase of contribution from higher margin products, such as Libod and Shusi; (ii) lower selling and distribution expenses; and (iii) significantly lower finance costs incurred during the year. As a consequence of improved operating results, profit for the year achieved RMB87.7 million, soared 41 times as compared with RMB2.1 million for the previous year. Core Profit Attributable to Equity Holders of the Company surged about 16 times to RMB103.4 million from RMB6.0 million in the previous year. In view of the sufficient cash flow and satisfactory operating results during the year, the board of directors of the Company recommended a final dividend of HK1 cent per share.

The Group has successfully transformed into an innovative comprehensive pharmaceutical company which integrated research, development, production and sales of the new drugs with its products of Class I new drugs and generic drugs, covering four major therapeutic areas such as oncology, central nervous system, liver and respiratory system. Performances of major products during the period are as follows:

1. Libod

Libod, also known as liposomal doxorubicin hydrochloride injection, is a product produced by FDZH with NT Pharma as the exclusive distributor. Libod applies to Level-I chemotherapy drugs, and is a good replacement for the traditional doxorubicin, with low cardiac toxicity, a stronger targeting capability, longer duration and better security. It was recommended by NCCN for Level-I application for the first time in 2015. The revenue from Libod increased by RMB279.2 million or 106.3% to RMB542.0 million, as compared with RMB262.8 million for the previous year. The strong growth in sales of Libod was partly due to the fact that Libod has steadily built up a demonstrable track record of safety and effectiveness in treating multiple types of cancer, in particular breast tumour and lymphoma, and partly due to NT Pharma's increased dedication and allocation of resources to its oncology business.

2. Shusi

Shusi, also known as quetiapine fumarate, is a proprietary product of Suzhou First. Shusi has a significant effect in treatment of the symptoms of schizophrenia and the manic eruption of bipolar emotional disorder. Of the total segment revenue, the revenue of Shusi increased by RMB62.8 million or 81.9% to RMB139.4 million, as compared with RMB76.6 million for the previous year. NT Pharma believes that Shusi has strong growth potential and will continue to play an important role in contributing to the Group's future growth strategies.

3. Songzhi Wan

Songzhi Wan is the only Chinese medicine capable of curing hepatitis Type C as approved by China Food and Drug Administration (CFDA), the development of which was included in the Major Scientific and Technical Breakthrough Program under the "10th Five-Year Plan" and the National High Technology Research and Development Program (863 Program). During the Stage I-II-III clinical research on Songzhi Wan, we proceeded in strict accordance with the principles of evidence-based medicine, and as a result, its drug efficacy and safety has been carefully verified with modern medicine, for which it was finally approved to enter the market with a certificate of new drug.

4. Xi Di Ke

Xi Di Ke, also known as uroacitides injection, is a proprietary product of Jiangsu Biopharma. Xi Di Ke, in combination with chemotherapy, is used in the treatment of advanced breast cancer and non-small cell lung cancer. In 2015, the study of treatment of myelodysplastic syndrome (MDS) with Xi Di Ke as well as its industrialization was included in the "Major New Drugs Innovation" Project Bank of the Ministry of Science and Technology.

Looking to the future, Mr. Ng Tit, Chairman and Chief Executive Officer of NT Pharma said: "Two innovative medicines, Songzhi Wan and Xi Di Ke will come into market in 2016, which will enrich the Group's existing and future product portfolio and bring huge innovative value to NT Pharma. The Group will be actively looking for opportunities to acquire new projects with significant potential, so as to largely improve our performance and create value for our shareholders."

Topic: Press release summary Sectors: Daily Finance, Daily News, BioTech
https://www.acnnewswire.com
From the Asia Corporate News Network